Q4 2022 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
JDQ443 - KRAS inhibitor
Financial review
Immunology
NCT05132075 KontRASt-02 (CJDQ443B12301)
Indication
Non-small cell lung cancer, 2/3L
Phase
Phase 3
Patients
360
Primary
Progression free survival (PFS)
Outcome
Measures
Arms
2023 priorities
Innovation: Clinical trials
Neuroscience
Intervention
Target
Patients
Arm 1 Experimental: JDQ443
Arm 2 Active Comparator: Participant will be treated with docetaxel following
local guidelines as per standard of care and product labels
Patients with advanced non-small cell lung cancer (NSCLC) harboring a KRAS
G12C mutation who have been previously treated with a platinum-based
chemotherapy and immune checkpoint inhibitor therapy either in sequence or
in combination.
Readout
Milestone(s)
2024
Publication
NA
86 Investor Relations | Q4 2022 Results
Oncology
Appendix
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation